Pharming Group
PHAR
4 hedge funds and large institutions have $230K invested in Pharming Group in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and closing their positions.
33% more funds holding
Funds holding: 3 → 4 (+1)
7% more capital invested
Capital invested by funds: $216K → $230K (+$14.5K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SBCM
Silverberg Bernstein Capital Management
Armonk,
New York
|
+$53.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$6.94K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$5.35K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SBCM
1
Silverberg Bernstein Capital Management
Armonk,
New York
| $196K | +$53.9K | +5,725 | +32% |
|
2
Morgan Stanley
New York
| $23.4K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $6.59K | +$6.94K | +737 | +1,417% |
|
|
4
Osaic Holdings
Scottsdale,
Arizona
| $4.74K | +$5.35K | +568 | New |
|
PHAR Hedge Fund Activity: Q2 2024 in Review
4 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Pharming Group (PHAR) for Q2 2024, worth a combined $230K — up 6.7% from $216K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new PHAR positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Silverberg Bernstein Capital Management, adding an estimated $53.9K.
- 4 institutional investors held Pharming Group (PHAR) as of Q2 2024, up from 3 in Q1 2024.
- Funds reported $230K of Pharming Group stock for Q2 2024, up 6.7% quarter-over-quarter.
- 1 fund opened new Pharming Group positions in Q2 2024 and 0 closed out, a net change of +1 holder.
- The largest Pharming Group buyer in Q2 2024 was Silverberg Bernstein Capital Management, an estimated $53.9K added.
Based on aggregated 13F filings for Q2 2024.